Based in Chassieu – France, AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector.
AMOEBA is continuing with its regulatory procedures so as to submit a request for provisional MA for all European countries in the first half of 2016, as soon as ANSES (French Agency for Food, Environmental and Occupational Health & Safety) has validated AMOEBA’s solution for the “air cooled towers” application.
In a worldwide market for chemical biocides estimated to be worth 21 bn€, AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT) estimated to be worth 1.7 bn€. Its disruptive technology complies with new regulations in terms of chemical emissions into the environment. AMOÉBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21 September last.